Loading...
Loading...
Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) shares inched up 0.1% to 62 cents, on giving an oral presentation highlighting the results of the phase I/II clinical trial of PRX-102 for the treatment of Fabry disease at a symposium in Rome. Share volume was 160,000, compared to an all-day average of 119,000
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in